Avenue Therapeutics, Inc. (ATXI)

Avenue Therapeutics, Inc. (ATXI) scores 29 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is 41.4, representing a 99% margin of safety.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full ATXI analysis on boothcheck